NCT03940352 - HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

August 20, 2024

Study Completion Date

August 20, 2024

Conditions

Acute Myeloid Leukemia (AML)High-risk Myelodysplastic Syndrome (MDS)

Interventions

DRUG

HDM201

Capsule

BIOLOGICAL

MBG453

LIVI (Liquid in vial) Concentrate for Solution for infusion

DRUG

Venetoclax

Tablet

Trial Locations (9)

Novartis Investigative Site, Melbourne

Novartis Investigative Site, Milan

Duke University Medical Center ., Durham

Novartis Investigative Site, Madrid

Novartis Investigative Site, Heidelberg

Novartis Investigative Site, Würzburg

Novartis Investigative Site, Singapore

Novartis Investigative Site, Helsinki

Novartis Investigative Site, Roma